The buzz around the India-US trade deal has pharmaceutical leaders beaming with assurance amid broader sectoral doubts. With unmatched affordability in drug manufacturing, India remains America’s linchpin for generics, and this pact will only tighten that grip.
Exclusive insights from Ketan Jota, Zota Healthcare’s Chairman, underscore India’s FDA-approved plant count—second only to the US—powering exports of vital generics and chronic disease fighters. Diabetes, hypertension, and thyroid meds top the list, fulfilling America’s insatiable appetite.
‘It’s a game-changer,’ Jota declared, praising PM Modi’s leadership for negotiating tariff relief in a deal that profits both sides—a feat rarely seen from the US.
The EU deal amplifies the wins by nullifying export duties, spurring higher volumes, tech transfers, and cheaper local production. Indian consumers stand to gain immensely from these efficiencies.
These pacts collectively propel India’s pharma industry toward greater export heights, global influence, and homegrown benefits. Expect a surge in trade, innovation, and accessible healthcare that reshapes lives on both sides of the equation.